M. T. Soler-Monsó

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.

C. Caldas, X. Puente, M. Pujana, 2019, Cancer research.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, A. Beck, 2020, npj Breast Cancer.

Modification of BRCA1-associated breast cancer risk by HMMR overexpression

C. Lázaro, R. Khokha, C. Eaves, 2022, Nature Communications.

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts

A. Green, F. Al-Shahrour, E. Rakha, 2021, bioRxiv.

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

A. Green, S. Lemeer, E. Rakha, 2021, Breast Cancer Research.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

F. Climent, M. Esteller, A. Urruticoechea, 2017, Stem cell reports.

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

A. Green, F. Al-Shahrour, E. Rakha, 2023, EMBO molecular medicine.